Repository logo
 
Publication

Behavioural Patterns in Allergic Rhinitis Medication in Europe: A Study Using MASK‐Air ® Real‐World Data

2022Journal article Open access
Simple item page
dc.contributor.authorSousa‐Pinto, B
dc.contributor.authorSá‐Sousa, A
dc.contributor.authorVieira, RJ
dc.contributor.authorAmaral, R
dc.contributor.authorKlimek, L
dc.contributor.authorCzarlewski, W
dc.contributor.authorAntó, JM
dc.contributor.authorPfaar, O
dc.contributor.authorBedbrook, A
dc.contributor.authorKvedariene, V
dc.contributor.authorVentura, MT
dc.contributor.authorAnsotegui, IJ
dc.contributor.authorBergmann, KC
dc.contributor.authorBrussino, L
dc.contributor.authorCanonica, GW
dc.contributor.authorCardona, V
dc.contributor.authorCarreiro‐Martins, P
dc.contributor.authorCasale, T
dc.contributor.authorCecchi, L
dc.contributor.authorChivato, T
dc.contributor.authorChu, DK
dc.contributor.authorCingi, C
dc.contributor.authorCosta, EM
dc.contributor.authorCruz, AA
dc.contributor.authorDe Feo, G
dc.contributor.authorDevillier, P
dc.contributor.authorFokkens, WJ
dc.contributor.authorGaga, M
dc.contributor.authorGemicioğlu, B
dc.contributor.authorHaahtela, T
dc.contributor.authorIvancevich, JC
dc.contributor.authorIspayeva, Z
dc.contributor.authorJutel, M
dc.contributor.authorKuna, P
dc.contributor.authorKaidashev, I
dc.contributor.authorKraxner, H
dc.contributor.authorLarenas‐Linnemann, DE
dc.contributor.authorLaune, D
dc.contributor.authorLipworth, B
dc.contributor.authorLouis, R
dc.contributor.authorMakris, M
dc.contributor.authorMonti, R
dc.contributor.authorMorais‐Almeida, M
dc.contributor.authorMösges, R
dc.contributor.authorMullol, J
dc.contributor.authorOdemyr, M
dc.contributor.authorOkamoto, Y
dc.contributor.authorPapadopoulos, NG
dc.contributor.authorPatella, V
dc.contributor.authorPham‐Thi, N
dc.contributor.authorRegateiro, FS
dc.contributor.authorReitsma, S
dc.contributor.authorRouadi, PW
dc.contributor.authorSamolinski, B
dc.contributor.authorSova, M
dc.contributor.authorTodo‐Bom, A
dc.contributor.authorTaborda‐Barata, L
dc.contributor.authorTomazic, PV
dc.contributor.authorToppila‐Salmi, S
dc.contributor.authorSastre, J
dc.contributor.authorTsiligianni, I
dc.contributor.authorValiulis, A
dc.contributor.authorVandenplas, O
dc.contributor.authorWallace, D
dc.contributor.authorWaserman, S
dc.contributor.authorYorgancioglu, A
dc.contributor.authorZidarn, M
dc.contributor.authorZuberbier, T
dc.contributor.authorFonseca, JA
dc.contributor.authorBousquet, J
dc.date.accessioned2023-03-21T12:38:46Z
dc.date.available2023-03-21T12:38:46Z
dc.date.issued2022
dc.description.abstractBackground: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. Methods: We analysed 2015-2020 MASK-air® European data. We compared days under no medication, monotherapy and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms ('VAS Global Symptoms') and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within 1 year. Results: We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median 'VAS Global Symptoms' was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p < .001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H1 -antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more. Conclusions: Allergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationAllergy . 2022 Sep;77(9):2699-2711pt_PT
dc.identifier.doi10.1111/all.15275pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/4466
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWileypt_PT
dc.subjectEurope / epidemiologypt_PT
dc.subjectHabitspt_PT
dc.subjectHistamine Antagonists / therapeutic usept_PT
dc.subjectRhinitis* / drug therapypt_PT
dc.subjectRhinitis, Allergic* / epidemiologypt_PT
dc.subjectHDE ALERpt_PT
dc.titleBehavioural Patterns in Allergic Rhinitis Medication in Europe: A Study Using MASK‐Air ® Real‐World Datapt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage2711pt_PT
oaire.citation.issue9pt_PT
oaire.citation.startPage2699pt_PT
oaire.citation.titleAllergypt_PT
oaire.citation.volume77pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Allergy 2022_2699.pdf
Size:
2.92 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ALER - Artigos